Geodesic
Electrochemical aptasensor for detection of lung cancer tumor markers in blood plasma
Žurnal Sibirskogo federalʹnogo universiteta. Matematika i fizika, Tome 17 (2024) no. 6, pp. 761-768.

Voir la notice de l'article provenant de la source Math-Net.Ru

The study investigates the possibility of diagnosing lung cancer through the simultaneous detection of six tumor biomarkers of this disease (CYFRA21-1, EpCAM, PLAUR, LIFR, ProGRP, and CEA) in blood plasma. The levels of these proteins in blood plasma were determined using square-wave voltammetry with multiplexed electrochemical chips modified with DNA aptamers. The results obtained in the study demonstrated the capability of the multiplex electrochemical aptasensor to simultaneously detect in blood plasma such traditionally used lung cancer tumor markers as CYFRA21-1, EpCAM, PLAUR, LIFR, ProGRP, and CEA.
Keywords: aptamers, lung cancer, electrochemical aptasensor, blood plasma tumor biomarkers. 
@article{JSFU_2024_17_6_a7,
     author = {Yuri E. Glazyrin and Galina S. Zamay and Anna S. Kichkailo and Tatiana N. Zamay and Yuri S. Pats and Sergei S. Zamay and Kirill A. Lukyanenko and Olga S. Kolovskaya},
     title = {Electrochemical aptasensor for detection of lung cancer tumor markers in blood plasma},
     journal = {\v{Z}urnal Sibirskogo federalʹnogo universiteta. Matematika i fizika},
     pages = {761--768},
     publisher = {mathdoc},
     volume = {17},
     number = {6},
     year = {2024},
     language = {en},
     url = {http://geodesic.mathdoc.fr/item/JSFU_2024_17_6_a7/}
}
TY  - JOUR
AU  - Yuri E. Glazyrin
AU  - Galina S. Zamay
AU  - Anna S. Kichkailo
AU  - Tatiana N. Zamay
AU  - Yuri S. Pats
AU  - Sergei S. Zamay
AU  - Kirill A. Lukyanenko
AU  - Olga S. Kolovskaya
TI  - Electrochemical aptasensor for detection of lung cancer tumor markers in blood plasma
JO  - Žurnal Sibirskogo federalʹnogo universiteta. Matematika i fizika
PY  - 2024
SP  - 761
EP  - 768
VL  - 17
IS  - 6
PB  - mathdoc
UR  - http://geodesic.mathdoc.fr/item/JSFU_2024_17_6_a7/
LA  - en
ID  - JSFU_2024_17_6_a7
ER  - 
%0 Journal Article
%A Yuri E. Glazyrin
%A Galina S. Zamay
%A Anna S. Kichkailo
%A Tatiana N. Zamay
%A Yuri S. Pats
%A Sergei S. Zamay
%A Kirill A. Lukyanenko
%A Olga S. Kolovskaya
%T Electrochemical aptasensor for detection of lung cancer tumor markers in blood plasma
%J Žurnal Sibirskogo federalʹnogo universiteta. Matematika i fizika
%D 2024
%P 761-768
%V 17
%N 6
%I mathdoc
%U http://geodesic.mathdoc.fr/item/JSFU_2024_17_6_a7/
%G en
%F JSFU_2024_17_6_a7
Yuri E. Glazyrin; Galina S. Zamay; Anna S. Kichkailo; Tatiana N. Zamay; Yuri S. Pats; Sergei S. Zamay; Kirill A. Lukyanenko; Olga S. Kolovskaya. Electrochemical aptasensor for detection of lung cancer tumor markers in blood plasma. Žurnal Sibirskogo federalʹnogo universiteta. Matematika i fizika, Tome 17 (2024) no. 6, pp. 761-768. http://geodesic.mathdoc.fr/item/JSFU_2024_17_6_a7/

[1] R.L.Siegel, K.D.Miller, A.Jemal, “Cancer statistics”, CA Cancer J. Clin., 70 (2020), 7–30 | DOI

[2] F.Bray, J.Ferlay, I.Soerjomataram, R.L.Siegel, L.A.Torre, A.Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”, CA Cancer J. Clin., 68 (2018), 394–424 | DOI

[3] M.B.Schabath, M.L.Cote, “Cancer progress and priorities: lung cancer”, Cancer Epidemiol. Biomarkers Prev., 28 (2019), 1563–1579 | DOI

[4] D.Jiang, X.Zhang, M.Liu et al., “Discovering Panel of Autoantibodies for Early Detection of Lung Cancer Based on Focused Protein Array”, Front. Immunol., 12 (2021), 658922 | DOI

[5] P.Villalobos, I.I.Wistuba, “Lung cancer biomarkers”, Hematol. Oncol. Clin. North. Am., 31 (2017), 13–29 | DOI

[6] N.Becker E.Motsch, A.Trotter, C.P.Heussel, H.Dienemann, P.A.Schnabel et al., “Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial”, Int. J. Cancer, 146 (2019), 1503–1513 | DOI

[7] B.Kowall, K.H.Jockel, A.Stang, “Lung cancer screening: current trends”, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 61 (2018), 1551–1558 | DOI

[8] D.Djureinovic, T.Dodig-Crnkovic, C.Hellstrom, G.Holgersson et al., “Detection of autoantibodies against cancer-testis antigens in non-small cell lung cancer”, Lung Cancer, 125 (2018), 157–163 | DOI

[9] N.S.Sergeeva, N.V.Marshutina, “General ideas about serological biomarkers and their place in oncology”, Practical Oncology, 12 (2011), 147–154 (in Russian)

[10] J.Wang, W.Jiang, T.Zhang, L.Liu, N.Bi, X.Wang et al., “Increased CYFRA 21-1, CEA and NSE are prognostic of poor outcome for locally advanced squamous cell carcinoma in lung: a nomogram and recursive partitioning risk stratification analysis”, Transl. Oncol., 11 (2018), 999–1006 | DOI

[11] T.Muley, V.Rolny, Y.He, B.Wehnl, A.Escherich, A.Warth et al., “The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)”, Lung Cancer, 120 (2018), 46–53 | DOI

[12] K.S.Song, S.B.Nimse, S.D.Warkad, A.C.Oh, T.Kim, Y.J.Hong, “Quantification of CYFRA 21-1 and a CYFRA 21-1-anti-CYFRA 21-1 autoantibody immune complex for detection of early stage lung cancer”, Chem. Commun., 55 (2019), 10060–10063 | DOI

[13] T.N.Zamay, G.S.Zamay, O.S.Kolovskaya, R.A.Zukov, M.M.Petrova, A.Gargaun, M.V.Berezovski, A.S.Kichkailo, “Current and Prospective Protein Biomarkers of Lung Cancer”, Cancers, 9:11 (2017), 155 | DOI

[14] D.H.Kim, J.M.Seo, K.J.Shin, “Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy”, Biomater. Res., 25 (2021), 42 | DOI

[15] G.S.Zamay, O.S.Kolovskaya, T.I.Ivanchenko et al., “Development of DNA aptamers to native EpCAM for isolation of lung circulating tumor cells from human blood”, Cancers, 11:3 (2019), 1–14 | DOI

[16] A.S.Zamay, G.S.Zamay, O.S.Kolovskaya, T.N.Zamay, M.V.Berezovsky, Method for selection of aptamers to specified protein targets on the cell surface, Russian Federation Patent, 2518368, 2012

[17] Yu.E.Glazyrin, A.V.Shabalina, K.A.Ryzhinskaya et al., “Screening of biomarker proteins of lung cancer using a multiplex electrochemical sensor system based on based on aptamers”, Bulletin of Siberian Medicine, 17:3 (2018), 13–21 (in Russian) | DOI

[18] P.Stieber, H.Dienemann, U.Hasholzner, “Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases”, International Journal of Biological Markers, 9:2 (1994), 82–88 | DOI

[19] A.E.Bastawisy, M.Elazzouny, G.Mohammed, A.Awadallah, E.Behiry, Serum cytokeratin 19 fragment in advanced lung cancer: could we eventually have a serum tumor marker?, Ecancer, 8:394 (2014), 1–9 | DOI

[20] D.Chen, Y.Sun, Y.Wei, P.Zhang, A.H.Rezaeian et al., “LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker”, Nature Medicine, 18 (2012), 1511–1517 | DOI

[21] Q.Huai, A.P.Mazar, A.Kuo, G.C.Parry et al., “Structure of Human Urokinase Plasminogen Activator in Complex with Its Receptor”, Science, 311 (2006), 656–659 | DOI

[22] R.Molina, X.Filella, J.M.Auge, “ProGRP: a new biomarker for small cell lung cancer”, Clin. Biochem., 37:7 (2004), 505–511 | DOI

[23] T.F.Bernardina, van der Gun, L.J.Melchers et al., “EpCAM in carcinogenesis: the good, the bad or the ugly”, Carcinogenesis, 31:11 (2010), 1913–1921 | DOI | MR

[24] B.Cacho-Diaz, H.Spinola-Marono, L.G.Mendoza-Olivas, A.Monroy-Sosa, G.Reyes-Soto, O.Arrieta, “Association of neurologic manifestations and CEA levels with the diagnosis of brain metastases in lung cancer patients”, Clin. Transl. Oncol., 21:11 (2019), 1538–1542 | DOI

[25] J.Yuan, Y.Sun, K.Wang et al., “Development and validation of reassigned CEA, CYFRA21-1 and NSE-based models for lung cancer diagnosis and prognosis prediction”, BMC Cancer, 22 (2022), 686 | DOI